Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Gilead sciences, inc. source : Www.biospace.com save search
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | $11.128 580
|
Communications
|
| O: -0.29%
H: 0.0%
C: 0.0%
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
CTXR | $0.746 -2.51% 230K
|
Health Technology
|
| O: 2.33%
H: 2.28%
C: -4.23%
hope treatment pharmaceuticals city for car-t trial
Leap Therapeutics Announces $40 Million Private Placement
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
LPTX | $3.11 3.67% 42K
|
Health Technology
|
| O: 15.13%
H: 25.43%
C: -11.0%
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
million leap therapeutics
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
Published: 2024-04-08 (Crawled : 23:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: -0.76%
H: 0.72%
C: 0.54%
gilead first sciences financial results
Gilead Sciences Announces Completion of Acquisition of CymaBay
Published: 2024-03-22 (Crawled : 22:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.03%
H: 0.16%
C: -0.68%
acquisition sciences
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
Published: 2024-03-06 (Crawled : 15:30) - biospace.com/
MRUS | $40.7 -1.38% 550K
|
Health Technology
|
| O: 0.06%
H: 1.66%
C: -2.56%
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: -0.15%
H: 0.6%
C: -0.34%
t-cell collaboration
Gilead Sciences CEO on Company's Evolution and Commitment to the Bay Area
Published: 2024-03-05 (Crawled : 14:30) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.21%
H: 0.84%
C: 0.81%
ceo bay sciences
Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
Published: 2024-02-26 (Crawled : 14:30) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: -0.07%
H: 0.53%
C: -0.75%
antiviral pipeline research
Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement
Published: 2024-02-20 (Crawled : 15:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.01%
H: 1.59%
C: 0.63%
antibody collaboration agreement
Gilead Sets Sights on Hepatitis C Elimination As It Marks 10 Years of Curative Therapies
Published: 2024-02-13 (Crawled : 14:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.32%
H: 0.11%
C: -1.55%
hepatitis
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Published: 2024-02-12 (Crawled : 14:30) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: -0.35%
H: 2.36%
C: 1.42%
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: 27.92%
H: 0.97%
C: 0.88%
liver acquisition sciences therapeutics
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy
Published: 2024-01-30 (Crawled : 15:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: -0.34%
H: 0.13%
C: -0.23%
yescarta fda t-cell change approval therapy
Gilead Provides Update on Phase 3 EVOKE-01 Study
Published: 2024-01-22 (Crawled : 14:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: -7.78%
H: 0.31%
C: -2.57%
evoke-01 update study
Lyndra Therapeutics Announces Positive Data from Pivotal Phase 3 Study with Oral Weekly Risperidone (LYN-005) for Schizophrenia
Published: 2024-01-04 (Crawled : 20:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.37%
H: 1.38%
C: 0.82%
lyn-005 positive schizophrenia therapeutics study
Lyndra Therapeutics Raises $101 Million in Series E Funding
Published: 2023-12-21 (Crawled : 15:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.29%
H: 0.76%
C: 0.14%
million series therapeutics funding
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
Published: 2023-12-20 (Crawled : 20:00) - biospace.com/
RDHL | $0.35 -13.41% 790K
|
Health Technology
|
| O: 9.09%
H: 20.83%
C: -2.78%
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.21%
H: 0.15%
C: -1.34%
rhb-107 ebola opaganib show
Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas
Published: 2023-12-12 (Crawled : 07:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.86%
H: 0.49%
C: 0.05%
yescarta t-cell lymphomas potential therapy
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers
Published: 2023-12-12 (Crawled : 07:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.86%
H: 0.49%
C: 0.05%
tecartus blood response potential
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
Published: 2023-12-11 (Crawled : 00:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.77%
H: 1.52%
C: 0.58%
yescarta t-cell response therapy
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.2%
H: 1.8%
C: 1.62%
trodelvy breast symposium cancer
Gilead Sciences to Present at Upcoming November 2023 Investor Conferences
Published: 2023-11-09 (Crawled : 09:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: -0.47%
H: 0.23%
C: -3.29%
sciences
Gainers vs Losers
| 53% | 47% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
PRSO | $1.99 56.69% 52M
|
Manufacturing
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.